The Immunoproteasome as a Target in Hematologic Malignancies

Seminars in Hematology

Volumn 49, Issue 3, 2012, Pages 258-262

  Kuhn, Deborah J ^a   Orlowski, Robert Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CALPEPTIN; CARFILZOMIB; DIHYDROEPONEMYCIN DERIVATIVE; IMMUNOPROTEASOME INHIBITOR; IPSI 001; ONX 0914; PR 924; PR 957; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER THERAPY; CELL PROTECTION; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; MYELOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS;

EID: 84862681257     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.04.003     Document Type: Article

References (37)

1. Buchdunger E., Zimmermann J., Mett H., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56:100-104.
2. Deininger M.W.N., Druker B.J. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003, 55:401-423.
3. Richardson P.G., Barlogie B., Berenson B., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
4. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
5. O'Connor O.A., Wright J., Moskowitz C., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676-684.
6. Bianchi G., Oliva L., Cascio P., et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2003, 113:3040-3049.
7. Voorhees P.M., Dees E.C., O'Neil B., Orlowski R.Z. The proteasome as a target for cancer therapy. Clin Cancer Res 2003, 9:6316-6325.
8. Lowe J., Stock D., Jap B., Zwickl P., Baumeister W., Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995, 268:533-539.
9. Unno M., Mizushima T., Morimoto Y., et al. Structure determination of the constitutive 20S proteasome from bovine liver at 2.75 A resolution. J Biochem 2002, 131:171-173.
10. Rivett A.J. The multicatalytic proteinase. Multiple proteolytic activities. J Biol Chem 1989, 264:12215-12219.
11. Kisselev A.F., Akopian T.N., Castillo V., Goldberg A.L. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell 1999, 4:395-402.
12. Jiang H., Monaco J.J. Sequence and expression of mouse proteasome activator PA28 and the related autoantigen Ki. Immunogenetics 1997, 46:93-98.
13. Noda C., Tanahashi N., Shimbara N., Hendil K.B., Tanaka K. Tissue distribution of constitutive proteasomes, immunoproteasomes, and PA28 in rats. Biochem Biophys Res Commun 2000, 277:348-354.
14. Parlati F., Lee S.J., Aujay M., et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009, 114:3439-3447.
15. Gaczynska M., Rock K.L., Spies T., Goldberg A.L. Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proc Natl Acad Sci U S A 1994, 91:9213-9217.
16. Gaczynska M., Rock K.L., Goldberg A.L. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993, 365:264-267.
17. Rock K.L., Goldberg A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999, 17:739-779.
18. Heink S., Ludwig D., Kloetzel P.-M., Krüger E. IFN-γ-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci U S A 2005, 102:9241-9246.
19. Shin E.C., Seifert U., Kato T., et al. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest 2006, 116:3006-3014.
20. Hallermalm K., Seki K., Wei C., et al. Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood 2001, 98:1108-1115.
21. Boes B., Hengel H., Ruppert T., Multhaup G., Koszinowski U.H., Kloetzel P.M. Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med 1994, 179:901-909.
22. Strehl B., Seifert U., Kruger E., Heink S., Kuckelkorn U., Kloetzel P.M. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev 2005, 207:19-30.
23. Rivett A.J., Hearn A.R. Proteasome function in antigen presentation: immunoproteasome complexes, peptide production, and interactions with viral proteins. Curr Protein Pept Sci 2004, 5:153-161.
24. Chu-Ping M., Vu J.H., Proske R.J., Slaughter C.A., DeMartino G.N. Identification, purification, and characterization of a high molecular weight, ATP-dependent activator (PA700) of the 20 S proteasome. J Biol Chem 1994, 269:3539-3547.
25. Hoffman L., Pratt G., Rechsteiner M. Multiple forms of the 20 S multicatalytic and the 26 S ubiquitin/ATP-dependent proteases from rabbit reticulocyte lysate. J Biol Chem 1992, 267:22362-22368.
26. Song X., von Kampen J., Slaughter C.A., DeMartino G.N. Relative functions of the alpha and beta subunits of the proteasome activator, PA28. J Biol Chem 1997, 272:27994-28000.
27. Ichikawa H.T., Conley T., Muchamuel T., et al. Novel proteasome inhibitors have a beneficial effect in murine lupus via the dual inhibition of type 1 interferon and autoantibody secreting cells. Arthritis Rheum 2012, 64:493-503.
28. Basler M., Dajee M., Moll C., Groettrup M., Kirk C.J. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 2010, 185:634-641.
29. Muchamuel T., Basler M., Aujay M.A., et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009, 15:781-787.
30. Visekruna A., Joeris T., Seidel D., et al. Proteasome-mediated degradation of IκBα and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 2006, 116:3195-3203.
31. Arastu-Kapur S., Anderl J.L., Kraus M., et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011, 17:2734-2743.
32. Kuhn D.J., Hunsucker S.A., Chen Q., Voorhees P.M., Orlowski M., Orlowski R.Z. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 2009, 113:4667-4676.
33. Orlowski M., Cardozo C., Eleuteri A.M., Kohanski R., Kam C.M., Powers J.C. Reactions of [C-14]-3,4-dichloroisocoumarin with subunits of pituitary and spleen multicatalytic proteinase complexes (proteasomes). Biochemistry 1997, 36:13946-13953.
34. Cardozo C., Michaud C., Orlowski M. Components of the bovine pituitary multicatalytic proteinase complex (proteasome) cleaving bonds after hydrophobic residues. Biochemistry 1999, 38:9768-9777.
35. Ho Y.K., Bargagna-Mohan P., Wehenkel M., Mohan R., Kim K.B. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol 2007, 14:419-430.
36. Kisselev A.F., Garcia-Calvo M., Overkleeft H.S., et al. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem 2003, 278:35869-35877.
37. Singh A.V., Bandi M., Aujay M.A., et al. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol 2011, 152:155-163.